Galit Weinstein

Galit Weinstein

Auto-generated profile, based on publicly available information

Galit Weinstein

School of Public Health, Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
GWGalit Weinstein
Galit Weinstein
SZShira Zelber-Sagi
Shira Zelber-Sagi
SPSarah R. Preis
Sarah R. Preis
ABAlexa S. Beiser
Alexa S. Beiser
CDCharles DeCarli
Charles DeCarli
SSSudha Seshadri
Sudha Seshadri
Nonalcoholic fatty liver disease (NAFLD) is emerging globally as the major cause of chronic liver disease,1 with a prevalence of approximately 30% in the general population and 80% among morbidly obese individuals.2,3 Lifestyle factors, including unhealthy diet and lack of physical activity, play a key role in the onset of NAFLD4,5 and their modification is the standard treatment.6 Insulin resistance, type 2 diabetes, and obesity are the strongest risk factors for NAFLD.1 However, a reciprocal association is also evident,7 in which NAFLD may lead to type 2 diabetes and metabolic syndrome independently from body weight8-12 or even visceral adiposity.13

9 June 2015 in Neurology
Verified
Journal Article
Closed access
PDF file
GWGalit Weinstein
Galit Weinstein
PMPauline Maillard
Pauline Maillard
JHJayandra J. Himali
Jayandra J. Himali
ABAlexa S. Beiser
Alexa S. Beiser
RARhoda Au
Rhoda Au
CDCharles DeCarli
Charles DeCarli
Objective: To evaluate the possible early consequences of impaired glucose metabolism on the brain by assessing the relationship of diabetes, fasting blood glucose (FBG) levels, and insulin resistance with cognitive performance and brain integrity in healthy young and middle-aged adults. Methods: The sample included dementia-free participants (mean age 40 ± 9 years; 53% women) of the Framingham Heart Study third-generation cohort with cognitive testing of memory, abstract reasoning, visual perception, attention, and executive function (n = 2,126). In addition, brain MRI examination (n = 1,597) was used to determine white matter, gray matter, and white matter hyperintensity (WMH) volumes and fractional anisotropy measures. We used linear regression models to assess relationships between diabetes, FBG, and insulin resistance with cognition, lobar gray matter, and WMH volumes as well as voxel-based microstructural white matter integrity and gray matter density, adjusting for potential confounders. Mediating effect of brain lesions on the association of diabetes with cognitive performance was also tested. Results: Diabetes was associated with worse memory, visual perception, and attention performance; increased WMH; and decreased total cerebral brain and occipital lobar gray matter volumes. The link of diabetes with attention and memory was mediated through occipital and frontal atrophy, and the latter also through hippocampal atrophy. Both diabetes and increased FBG were associated with large areas of reductions in gray matter density and fractional anisotropy on voxel-based analyses. Conclusions: We found that hyperglycemia is associated with subtle brain injury and impaired attention and memory even in young adults, indicating that brain injury is an early manifestation of impaired glucose metabolism.

2 June 2019 in Liver International
Verified
Journal Article
Closed access
PDF file
GWGalit Weinstein
Galit Weinstein
KDKendra Davis‐Plourde
Kendra Davis‐Plourde
JHJayandra J. Himali
Jayandra J. Himali
SZShira Zelber‐Sagi
Shira Zelber‐Sagi
ABAlexa S. Beiser
Alexa S. Beiser
SSSudha Seshadri
Sudha Seshadri

15 February 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GWGalit Weinstein
Galit Weinstein
KDKendra L. Davis-Plourde
Kendra L. Davis-Plourde
SCSarah Conner
Sarah Conner
JHJayandra J. Himali
Jayandra J. Himali
ABAlexa S. Beiser
Alexa S. Beiser
SSSudha Seshadri
Sudha Seshadri
To determine whether classes of diabetes medications are associated with cognitive health and dementia risk, above and beyond their glycemic control properties. Findings were pooled from 5 population-based cohorts: the Framingham Heart Study, the Rotterdam Study, the Atherosclerosis Risk in Communities (ARIC) Study, the Aging Gene-Environment Susceptibility-Reykjavik Study (AGES) and the Sacramento Area Latino Study on Aging (SALSA). Differences between users and non-users of insulin, metformin and sulfonylurea were assessed in each cohort for cognitive and brain MRI measures using linear regression models, and cognitive decline and dementia/AD risk using mixed effect models and Cox regression analyses, respectively. Findings were then pooled using meta-analytic techniques, including 3,590 individuals with diabetes for the prospective analysis. After adjusting for potential confounders including indices of glycemic control, insulin use was associated with increased risk of new-onset dementia (pooled HR (95% CI) = 1.58 (1.18, 2.12);p = 0.002) and with a greater decline in global cognitive function (β = -0.014±0.007;p = 0.045). The associations with incident dementia remained similar after further adjustment for renal function and excluding persons with diabetes whose treatment was life-style change only. Insulin use was not related to cognitive function nor to brain MRI measures. No significant associations were found between metformin or sulfonylurea use and outcomes of brain function and structure. There was no evidence of significant between-study heterogeneity. Despite its advantages in controlling glycemic dysregulation and preventing complications, insulin treatment may be associated with increased adverse cognitive outcomes possibly due to a greater risk of hypoglycemia.

23 May 2017 in BMC Neurology
Verified
Journal Article
Open access
PDF file
Anders WallinAnders Wallin
Anders Wallin
Elisabeth KapakiElisabeth Kapaki
Elisabeth Kapaki
MBM. Boban
M. Boban
SES. Engelborghs
S. Engelborghs
Dirk HermannDirk Hermann
Dirk Hermann
GRGary A. Rosenberg
Gary A. Rosenberg
Vascular cognitive impairment (VCI) is a heterogeneous entity with multiple aetiologies, all linked to underlying vascular disease. Among these, VCI related to subcortical small vessel disease (SSVD) is emerging as a major homogeneous subtype. Its progressive course raises the need for biomarker identification and/or development for adequate therapeutic interventions to be tested. In order to shed light in the current status on biochemical markers for VCI-SSVD, experts in field reviewed the recent evidence and literature data. The group conducted a comprehensive search on Medline, PubMed and Embase databases for studies published until 15.01.2017. The proposal on current status of biochemical markers in VCI-SSVD was reviewed by all co-authors and the draft was repeatedly circulated and discussed before it was finalized. This review identifies a large number of biochemical markers derived from CSF and blood. There is a considerable overlap of VCI-SSVD clinical symptoms with those of Alzheimer’s disease (AD). Although most of the published studies are small and their findings remain to be replicated in larger cohorts, several biomarkers have shown promise in separating VCI-SSVD from AD. These promising biomarkers are closely linked to underlying SSVD pathophysiology, namely disruption of blood-CSF and blood–brain barriers (BCB-BBB) and breakdown of white matter myelinated fibres and extracellular matrix, as well as blood and brain inflammation. The leading biomarker candidates are: elevated CSF/blood albumin ratio, which reflects BCB/BBB disruption; altered CSF matrix metalloproteinases, reflecting extracellular matrix breakdown; CSF neurofilment as a marker of axonal damage, and possibly blood inflammatory cytokines and adhesion molecules. The suggested SSVD biomarker deviations contrasts the characteristic CSF profile in AD, i.e. depletion of amyloid beta peptide and increased phosphorylated and total tau. Combining SSVD and AD biomarkers may provide a powerful tool to identify with greater precision appropriate patients for clinical trials of more homogeneous dementia populations. Thereby, biomarkers might promote therapeutic progress not only in VCI-SSVD, but also in AD.

14 July 2016 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
ECErica C. Camargo
Erica C. Camargo
GWGalit Weinstein
Galit Weinstein
ABAlexa S. Beiser
Alexa S. Beiser
ZTZaldy S. Tan
Zaldy S. Tan
CDCharles DeCarli
Charles DeCarli
SSSudha Seshadri
Sudha Seshadri
Background: Handgrip strength and gait speed are simple measures of physical capability and have been associated with current and future health outcomes. However, studies on their associations with brain structure and function in middle-aged adults are lacking. Objective: To assess the relationship of fast-paced walking speed and handgrip strength with risk of dementia, Alzheimer’s disease (AD), and stroke, as well as the cross-sectional associations with cognitive and brain magnetic resonance imaging (MRI) measures in a middle-aged community sample. Methods: Framingham Offspring ( n = 2,176; mean age 62, 54% female) had physical function, brain MRI, and cognitive evaluations between 1999 and 2005 and were followed-up for incident dementia AD and stroke until 11 years later. We related walking speed and handgrip strength to incident dementia, AD, and stroke using Cox models, and to brain and cognitive measures using multivariable linear and logistic regression. Models were adjusted for age, sex, education, and vascular risk factors. Results: Slow walking and weak handgrip were associated with more than 2.5-fold increase in risk of AD. Weaker handgrip was associated with an increased risk of incident stroke (HR 1.74, 95% CI: 1.12–2.70/SDU, p = 0.01) in persons ≥65 years. Both measures were associated with lower total brain volume and poorer performance on tests of visual memory, language, executive function, and visuoperceptual function. Slower gait was also related to poorer verbal memory, and weaker handgrip to poorer abstraction. Conclusion: Tests of walking speed and handgrip strength may serve as clinical markers of brain structure and function and may improve dementia risk prediction.